Receptor-Interacting Protein Kinase 2 (RIPK2) Stabilizes C-myc and Is a Therapeutic Target in Prostate Cancer Metastasis

By
Justin.choi
-
0
10
Scientists showed RIPK2 was a clinically actionable target for inhibiting prostate cancer (PC) metastasis. RIPK2 was amplified/gained in ~65% of lethal metastatic castration-resistant PC.
[Nature Communications]

Sorry, but the selected Zotpress account can't be found.

Full Article